| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 22nd December 2020 | Partners L P/Il Bvf | 509,410 | Conversion of derivative | $0.00 | |
| 22nd December 2020 | Partners L P/Il Bvf | 11,278 | Conversion of derivative | $0.00 | |
| 22nd December 2020 | Partners L P/Il Bvf | 97,615 | Conversion of derivative | $0.00 | |
| 22nd December 2020 | Partners L P/Il Bvf | 1,944 | Conversion of derivative | $0.00 | |
| 22nd December 2020 | Partners L P/Il Bvf | 654,215 | Conversion of derivative | $0.00 | |
| 22nd December 2020 | Partners L P/Il Bvf | 15,166 | Conversion of derivative | $0.00 | |
| 17th December 2020 | Capital Management, Llc Aquilo | 250,000 | Open or private sale | $18.81 | $4,703,225.00 |
| 16th December 2020 | Capital Management, Llc Aquilo | 14,933 | Open or private sale | $18.62 | $278,034.54 |
| 9th December 2020 | Partners L P/Il Bvf | 166,194 | Open or private sale | $18.00 | $2,991,492.00 |
| 9th December 2020 | Partners L P/Il Bvf | 239,274 | Open or private sale | $18.00 | $4,306,932.00 |
Pieris Pharmaceuticals
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas.
Ticker: PIRS
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1583648
Employees: 127
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $44 M (-28%)
Assets, Current: $92 M (-19%)
Property, Plant and Equipment, Net: $21 M (0%)
Other Assets, Noncurrent: $2 M (-37%)
Assets: $118 M (-16%)
Accounts Payable, Current: $4 M (-24%)
Accrued Liabilities, Current: $6 M (-40%)
Liabilities, Current: $18 M (-32%)
Liabilities: $71 M (-20%)
Common Stock, Value, Issued: $52 Th (-5%)
Common Stock, Shares, Issued: $52 M (-5%)
Additional Paid in Capital, Common Stock: $230 M (1%)
Retained Earnings (Accumulated Deficit): $183 M (4%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 M (-46%)
Stockholders' Equity (Parent): $47 M (0%)
Liabilities and Equity: $118 M (-16%)
Research and Development: $11 M (-52%)
General and Administrative Expenses: $5 M (-48%)
Operating Income/Loss: $5 M (-45%)
News
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
